RaySearch enters into interoperability agreement with Varian
RaySearch Laboratories AB (publ) and Varian Medical Systems have entered into an interoperability agreement that will allow the RayCare®* oncology information system to connect to Varian TrueBeam linear accelerators.
The ability to schedule radiation treatments and keep track of the treatment progress is a key functionality in an oncology information system. Under the announced agreement, a dedicated interface has been defined which allows RayCare and Varian TrueBeam to communicate the data necessary for an integrated workflow. This means that clinics will be able to use RayCare to manage all clinical activities around their Varian TrueBeam accelerators.
The development of the interface is already ongoing, and the target is to release it before the end of 2020. Commercial availability will be subject to regulatory clearance in some markets.
Johan Löf, founder and CEO at RaySearch, says: “We are constantly working to add support for more treatment machines in RayCare, and I’m very happy that we have now entered into this agreement. Interoperability with Varian TrueBeam will significantly expand the market potential for RayCare and improve the workflow for our existing customers.”
This information is information that RaySearch Laboratories AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication through the agency of the contact persons set out above at 13:00 CEST on May 28, 2020.
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets worldwide its treatment planning system RayStation and next-generation oncology information system RayCare. Over 2,600 clinics in more than 65 countries use RaySearch software to improve lives and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.
RayCare is designed to support the complex logistical challenges of modern oncology clinics. It represents the future of oncology information system technology, supporting the vision of one oncology workflow. Many cancer patients receive a combination of treatment types, and RayCare is designed to reflect that. It will efficiently coordinate activities in radiation therapy, chemotherapy and surgery and will offer advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy. RayCare is being developed with tomorrow’s requirements for advanced analytics and decision support in mind.
* Subject to regulatory clearance in some markets.
Find more information about RaySearch at www.raysearchlabs.com
For further information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
Peter Thysell, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)70 661 05 59